These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 17978853)

  • 21. Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population.
    Sugimoto K; Uno T; Yamazaki H; Tateishi T
    Br J Clin Pharmacol; 2008 Mar; 65(3):437-9. PubMed ID: 18241287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic polymorphisms of drug-metabolizing phase I enzymes CYP2E1, CYP2A6 and CYP3A5 in South Indian population.
    Krishnakumar D; Gurusamy U; Dhandapani K; Surendiran A; Baghel R; Kukreti R; Gangadhar R; Prayaga U; Manjunath S; Adithan C
    Fundam Clin Pharmacol; 2012 Apr; 26(2):295-306. PubMed ID: 21265876
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic polymorphism of cytochrome P450 2C19 in healthy Malaysian subjects.
    Pang YS; Wong LP; Lee TC; Mustafa AM; Mohamed Z; Lang CC
    Br J Clin Pharmacol; 2004 Sep; 58(3):332-5. PubMed ID: 15327595
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population.
    Halling J; Petersen MS; Damkier P; Nielsen F; Grandjean P; Weihe P; Lundgren S; Lundblad MS; Brøsen K
    Eur J Clin Pharmacol; 2005 Aug; 61(7):491-7. PubMed ID: 16025294
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations.
    Allabi AC; Gala JL; Desager JP; Heusterspreute M; Horsmans Y
    Br J Clin Pharmacol; 2003 Dec; 56(6):653-7. PubMed ID: 14616425
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance.
    Rosemary J; Adithan C
    Curr Clin Pharmacol; 2007 Jan; 2(1):93-109. PubMed ID: 18690857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Mongolian population in China.
    Yang ZF; Cui HW; Hasi T; Jia SQ; Gong ML; Su XL
    Genet Mol Res; 2010 Sep; 9(3):1844-51. PubMed ID: 20845310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Cytochrome P450 2C19 gene polymorphism in four Chinese nationality populations].
    Zhang S; Dong Z; Tang L; Zhou Q; Wu Z
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2002 Feb; 19(1):52-4. PubMed ID: 11836688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic polymorphism of CYP2D6 and CYP2C19 in east- and southern African populations including psychiatric patients.
    Dandara C; Masimirembwa CM; Magimba A; Sayi J; Kaaya S; Sommers DK; Snyman JR; Hasler JA
    Eur J Clin Pharmacol; 2001 Apr; 57(1):11-7. PubMed ID: 11372584
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific islands.
    Kaneko A; Lum JK; Yaviong L; Takahashi N; Ishizaki T; Bertilsson L; Kobayakawa T; Björkman A
    Pharmacogenetics; 1999 Oct; 9(5):581-90. PubMed ID: 10591538
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Variability in CYP2C9 allele frequency: a pilot study of its predicted impact on warfarin response among healthy South and North Indians.
    Nahar R; Deb R; Saxena R; Puri RD; Verma IC
    Pharmacol Rep; 2013; 65(1):187-94. PubMed ID: 23563037
    [TBL] [Abstract][Full Text] [Related]  

  • 32. S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians.
    Persson I; Aklillu E; Rodrigues F; Bertilsson L; Ingelman-Sundberg M
    Pharmacogenetics; 1996 Dec; 6(6):521-6. PubMed ID: 9014201
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects.
    Hulot JS; Bura A; Villard E; Azizi M; Remones V; Goyenvalle C; Aiach M; Lechat P; Gaussem P
    Blood; 2006 Oct; 108(7):2244-7. PubMed ID: 16772608
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of the CYP2C19 polymorphism in a North-eastern Thai population.
    Tassaneeyakul W; Tawalee A; Tassaneeyakul W; Kukongviriyapan V; Blaisdell J; Goldstein JA; Gaysornsiri D
    Pharmacogenetics; 2002 Apr; 12(3):221-5. PubMed ID: 11927837
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacogenetics and psychopharmacotherapy.
    Poolsup N; Li Wan Po A; Knight TL
    J Clin Pharm Ther; 2000 Jun; 25(3):197-220. PubMed ID: 10886465
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CYP2C19 polymorphism as a predictor of personalized therapy in South Indian population.
    Siddapuram SP; Banerjee R; Tandan M; Prathap N; Mitnal S; Duvvuru NR
    J Assoc Physicians India; 2011 Aug; 59():490-3. PubMed ID: 21887904
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The role of CYP2C19 polymorphism in the development of adverse effects to drugs and the risk for diseases].
    Alonso-Navarro H; Jiménez-Jiménez FJ; García-Agúndez JA
    Med Clin (Barc); 2006 May; 126(18):697-706. PubMed ID: 16759580
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of the CYP2C9 AND CYP2C19 polymorphisms on phenytoin hydroxylation in healthy individuals from south India.
    Rosemary J; Surendiran A; Rajan S; Shashindran CH; Adithan C
    Indian J Med Res; 2006 May; 123(5):665-70. PubMed ID: 16873909
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic Polymorphism of Drug-Metabolizing Enzymes CYP2C9 and CYP2C19 in Moroccan Population.
    Afilal D; Basselam MA; Brakez Z; Chouham S; Brehm A; Izaabel EH
    Genet Test Mol Biomarkers; 2017 May; 21(5):298-304. PubMed ID: 28282224
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of CYP2C19 polymorphisms in the Lebanese population.
    Djaffar Jureidini I; Chamseddine N; Keleshian S; Naoufal R; Zahed L; Hakime N
    Mol Biol Rep; 2011 Nov; 38(8):5449-52. PubMed ID: 21380557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.